Improvement of Aptamer Affinity by Dimerization

To increase the affinities of aptamers for their targets, we designed an aptamer dimer for thrombin and VEGF. This design is based on the avidity of the antibody, which enables the aptamer to connect easily since it is a single-strand nucleic acid. In this study, we connected a 15-mer thrombin-binding aptamer with a 29-mer thrombin-binding aptamer. Each aptamer recognizes a different part of the thrombin molecule, and the aptamer dimer has a Kd value which is 1/10 of that of the monomers from which it is composed. Also, the designed aptamer dimer has higher inhibitory activity than the reported (15-mer) thrombin-inhibiting aptamer. Additionally, we connected together two identical aptamers against vascular endothelial growth factor (VEGF165), which is a homodimeric protein. As in the case of the anti-thrombin aptamer, the dimeric anti-VEGF aptamer had a much lower Kd value than that of the monomer. This study demonstrated that the dimerization of aptamers effectively improves the affinities of those aptamers for their targets.

[1]  Koji Sode,et al.  Selection of DNA aptamers against VEGF165 using a protein competitor and the aptamer blotting method , 2008, Biotechnology Letters.

[2]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[3]  Kazunori Ikebukuro,et al.  Aptamer selection based on inhibitory activity using an evolution-mimicking algorithm. , 2006, Biochemical and biophysical research communications.

[4]  G. Adams,et al.  Generating improved single-chain Fv molecules for tumor targeting. , 1999, Journal of immunological methods.

[5]  M F Kubik,et al.  Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. , 1997, Journal of molecular biology.

[6]  A. D. de Vos,et al.  Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[7]  G. Mayer,et al.  Multidomain Targeting Generates a High‐Affinity Thrombin‐Inhibiting Bivalent Aptamer , 2007, Chembiochem : a European journal of chemical biology.

[8]  U. Landegren,et al.  Protein detection using proximity-dependent DNA ligation assays , 2002, Nature Biotechnology.

[9]  E. Vermaas,et al.  Selection of single-stranded DNA molecules that bind and inhibit human thrombin , 1992, Nature.

[10]  L. Zardi,et al.  Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. , 1999, Cancer research.

[11]  K. Hagihara,et al.  Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[12]  P. Garnero,et al.  Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses. , 2007, Cancer treatment reviews.

[13]  G. Winter,et al.  High-affinity antigen binding by chelating recombinant antibodies (CRAbs). , 1995, Journal of molecular biology.

[14]  S. Jayasena.  Aptamers: an emerging class of molecules that rival antibodies in diagnostics. , 1999, Clinical chemistry.

[15]  N. Skelton,et al.  Refinement of the solution structure of the heparin-binding domain of vascular endothelial growth factor using residual dipolar couplings , 2002, Journal of biomolecular NMR.

[16]  K. Ikebukuro,et al.  Homogeneous DNA sensing using enzyme-inhibiting DNA aptamers , 2006, Biochemical and Biophysical Research Communications.

[17]  K. Ikebukuro,et al.  Aptameric enzyme subunit for biosensing based on enzymatic activity measurement. , 2006, Analytical chemistry.

[18]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.